Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

ClinicalTrials.gov ID: NCT06764875

Public ClinicalTrials.gov record NCT06764875. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Sep 8, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.

Study identification

NCT ID
NCT06764875
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
840 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2025
Primary completion
Apr 26, 2029
Completion
Dec 8, 2030
Last update posted
Jun 15, 2026

2025 – 2030

United States locations

U.S. sites
54
U.S. states
29
U.S. cities
51
Facility City State ZIP Site status
Research Site Anchorage Alaska 99508 Recruiting
Research Site Phoenix Arizona 85054 Recruiting
Research Site Duarte California 91010 Recruiting
Research Site Glendale California 91204 Not yet recruiting
Research Site La Jolla California 92037 Recruiting
Research Site Los Alamitos California 90720 Not yet recruiting
Research Site Los Angeles California 90089 Recruiting
Research Site Santa Monica California 90404 Recruiting
Research Site Solvang California 93463 Recruiting
Research Site Upland California 91786 Recruiting
Research Site Walnut Creek California 94598 Recruiting
Research Site Aurora Colorado 80045 Recruiting
Research Site Newark Delaware 19713 Not yet recruiting
Research Site Jacksonville Florida 32207 Not yet recruiting
Research Site Jacksonville Florida 32224 Recruiting
Research Site Orlando Florida 32806 Recruiting
Research Site Athens Georgia 30607 Withdrawn
Research Site Marietta Georgia 30060 Recruiting
Research Site Chicago Illinois 60612 Recruiting
Research Site Chicago Illinois 60637 Not yet recruiting
Research Site Evanston Illinois 60201 Not yet recruiting
Research Site Hinsdale Illinois 60521 Recruiting
Research Site Niles Illinois 60714 Recruiting
Research Site Dyer Indiana 46311 Withdrawn
Research Site Waukee Iowa 50263 Not yet recruiting
Research Site Louisville Kentucky 40217 Recruiting
Research Site Silver Spring Maryland 20904 Recruiting
Research Site Boston Massachusetts 02114 Withdrawn
Research Site Boston Massachusetts 02118 Withdrawn
Research Site Detroit Michigan 48202 Recruiting
Research Site Grand Rapids Michigan 49503 Recruiting
Research Site Burnsville Minnesota 55337 Recruiting
Research Site Kansas City Missouri 64111 Withdrawn
Research Site St Louis Missouri 63108 Recruiting
Research Site Omaha Nebraska 68198-5885 Recruiting
Research Site Reno Nevada 89502 Recruiting
Research Site Summit New Jersey 07901 Not yet recruiting
Research Site Santa Fe New Mexico 87505 Recruiting
Research Site New Hyde Park New York 11042 Withdrawn
Research Site New York New York 10021 Recruiting
Research Site Cincinnati Ohio 45220 Recruiting
Research Site Columbus Ohio 43221 Recruiting
Research Site Oklahoma City Oklahoma 73104 Not yet recruiting
Research Site Philadelphia Pennsylvania 19104 Not yet recruiting
Research Site Knoxville Tennessee 37909 Recruiting
Research Site Nashville Tennessee 37232 Withdrawn
Research Site Dallas Texas 75246 Recruiting
Research Site Round Rock Texas 78665 Not yet recruiting
Research Site Webster Texas 77598 Recruiting
Research Site Charlottesville Virginia 22908 Recruiting
Research Site Fairfax Virginia 22031 Withdrawn
Research Site Richmond Virginia 23235 Withdrawn
Research Site Charleston West Virginia 25304 Recruiting
Research Site Madison Wisconsin 53792 Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 237 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06764875, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 15, 2026 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06764875 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →